Stockscreener 앱 받기
10.84
0.73%
-0.08
전일 마감가:
$10.92
열려 있는:
$10.94
하루 거래량:
961.47K
Relative Volume:
1.15
시가총액:
$619.34M
수익:
$20.72M
순이익/손실:
$-100.84M
주가수익비율:
-4.0752
EPS:
-2.66
순현금흐름:
$-78.56M
1주 성능:
+1.31%
1개월 성능:
-1.19%
6개월 성능:
+140.89%
1년 성능:
+57.56%
1일 변동 폭
$10.71
$11.60
1주일 범위
$10.30
$11.60
52주 변동 폭
$2.235
$12.34
4D몰큘러 테라퓨틱스 Stock (FDMT) Company Profile
명칭
4 D Molecular Therapeutics Inc
전화
(510) 505-2680
주소
5858 HORTON STREET #455, EMERYVILLE
FDMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
10.84 | 623.92M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
4D몰큘러 테라퓨틱스 Stock (FDMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-07 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | 개시 | Morgan Stanley | Underweight |
| 2024-09-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | 개시 | Barclays | Overweight |
| 2024-02-07 | 재개 | Goldman | Buy |
| 2023-10-26 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-18 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-01-30 | 개시 | BMO Capital Markets | Outperform |
| 2022-11-18 | 개시 | H.C. Wainwright | Buy |
| 2022-11-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-12 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 개시 | Jefferies | Buy |
| 2022-01-04 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | BofA Securities | Buy |
| 2021-01-05 | 개시 | Evercore ISI | Outperform |
| 2021-01-05 | 개시 | Goldman | Neutral |
모두보기
4D몰큘러 테라퓨틱스 주식(FDMT)의 최신 뉴스
4DMT Announces New Employment Inducement Grants - GlobeNewswire
4D Molecular Therapeutics expands phase 3 trial enrollment - MSN
4D Molecular Therapeutics Expands Phase 3 Trial Enrollment - TipRanks
4D Molecular Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire
4D Molecular Therapeutics Advances in Macular Degeneration Treatment: A Phase 3 Study Update - MSN
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Decheng Capital LLC - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Down 7.4%Here's What Happened - MarketBeat
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - MSN
4D Molecular Therapeutics Reports Strategic Gains in Q3 2025 - MSN
How interest rate cuts could boost 4D Molecular Therapeutics Inc. stockGlobal Markets & Safe Capital Investment Plans - BỘ NỘI VỤ
4D Molecular Therapeutics taps Kristian Humer as CFO - MSN
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
4D Molecular Therapeutics Appoints New Financial Officer - MSN
Transcript : 4D Molecular Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 09 - marketscreener.com
FDMT SEC Filings4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insider Selling: 4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,314.65 in Stock - MarketBeat
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2%What's Next? - MarketBeat
4D Molecular Therapeutics (NASDAQ: FDMT) to join Evercore Healthcare Conference fireside chat - Stock Titan
4d Molecular Therapeutics chief legal officer sells $17k in stock - Investing.com Canada
[Form 4] 4D Molecular Therapeutics, Inc. Insider Trading Activity - Stock Titan
4D Molecular Therapeutics Executive Sells Shares - TradingView
Officer Bizily Sells 1,635 ($17.3K) Of 4D Molecular Therapeutics Inc [FDMT] - TradingView
Published on: 2025-11-19 17:30:27 - newser.com
Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
4D Molecular Therapeutics Secures Up to $11M More from CF Foundation to Accelerate 4D-710 Development - MSN
What recovery options are there for 4D Molecular Therapeutics Inc.July 2025 Catalysts & Capital Efficiency Focused Strategies - newser.com
FDMT: 4D-150 achieves up to 92% injection reduction in wet AMD, with global phase III trials underway - TradingView
FDMT: 4D-150 gene therapy offers up to 92% injection reduction and strong safety for retinal disease - TradingView
4D Molecular Therapeutics appoints Kristian Humer as chief financial officer By Investing.com - Investing.com Nigeria
4D Molecular Therapeutics Names Kristian Humer as CFO - MarketScreener
4D Molecular Therapeutics appoints Kristian Humer as chief financial officer - Investing.com
4D Molecular Therapeutics Appoints New Chief Financial Officer - TipRanks
4D Molecular (FDMT) Therapeutics Appoints New CFO to Drive Finan - GuruFocus
4DMT Appoints Kristian Humer as Chief Financial Officer - The Globe and Mail
4D Molecular Therapeutics Appoints New CFO - TradingView
4D Molecular Therapeutics Appoints Kristian Humer as Chief Financial Officer | FDMT Stock News - Quiver Quantitative
[8-K] 4D Molecular Therapeutics, Inc. Reports Material Event | FDMT SEC FilingForm 8-K - Stock Titan
4D Molecular Therapeutics (NASDAQ:FDMT) Upgraded at Wall Street Zen - MarketBeat
4D Molecular Therapeutics Inc. (FDMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
FY2025 Earnings Forecast for FDMT Issued By Chardan Capital - MarketBeat
Can 4D Molecular Therapeutics Inc. rally from current levelsMarket Growth Summary & Free Expert Approved Momentum Trade Ideas - newser.com
4DMT (NASDAQ: FDMT) grants 45,400 RSUs to four new employees under 2025 inducement plan - Stock Titan
Leerink Partnrs Issues Pessimistic Outlook for FDMT Earnings - MarketBeat
Promising Outlook for 4D Molecular Therapeutics: Buy Rating Backed by Strategic Partnerships and Strong Financial Position - TipRanks
Institutional investors own a significant stake of 49% in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - simplywall.st
Barclays Maintains 4D Molecular Therapeutics (FDMT) Overweight Recommendation - Nasdaq
4D Molecular Therapeutics Misses On Revenue But Secures New Funding - Finimize
Working capital per share of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView
4D Molecular Therapeutics: Financial Backing Strengthens Clinical Pipeline Prospects - Ad-hoc-news.de
4D몰큘러 테라퓨틱스 (FDMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):